ARTICLE

Volume 10,Issue 4

Cite this article
4
Citations
20
Views
26 December 2025

Application of Denosumab Injection Combined with Basic Treatment in the Treatment of Elderly Female Patients with Osteoporosis

Yu Qian1 Meili Hu*
Show Less
1 Jiangsu Provincial Government Hospital, Nanjing 210000, Jiangsu, China
JMDS 2025 , 10(4), 102–107; https://doi.org/10.18063/JMDS.v10i4.1193
© 2025 by the Author. Licensee Whioce Publishing, Singapore. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC BY-NC 4.0) ( https://creativecommons.org/licenses/by-nc/4.0/ )
Abstract

Objective: To explore the application effect of denosumab injection combined with basic treatment in the treatment of elderly female patients with osteoporosis. Methods: The elderly female patients with osteoporosis in our hospital from 2024.1 to 2025.7 were included. The total sample size included was 60 cases. They were divided into groups using the ball-touching method and different clinical treatments were carried out. The sample size included in the control group and the observation group were 30 cases. The corresponding treatment plan was basic treatment, denosumab injection combined with basic treatment. Results: The total effective rate of treatment in the observation group (96.67%) was higher than that in the control group (73.33%), P<0.05. The differences between the groups in electrolyte elements and bone metabolism indicators were small at the time of enrollment. After treatment, the levels of blood phosphorus, blood calcium, and bone alkaline phosphatase in the observation group were higher than those in the control group, and the level of type I collagen carboxyl terminal peptide β special sequence in the observation group was lower than that in the control group, P<0.05. The difference in bone density between the groups was small at the time of enrollment. After treatment, the bone density levels of lumbar spine L2-4 and total hip joint in the observation group were higher than those in the control group, P<0.05. There was no significant difference in the incidence of adverse reactions between the observation group and the control group (13.33%, 10.00%). The drug safety was equivalent between the groups, P>0.05. Conclusion: Elderly female patients with osteoporosis who receive denosumab injection combined with basic treatment have significant value in improving patient efficacy, improving electrolyte elements, bone metabolism, and bone density indicators, and are highly safe.

Keywords
osteoporosis
denosumab
efficacy
electrolytes
bone metabolism
bone density
References

[1] Fan DS, Zheng LY, Wu YT, 2025, Clinical Efficacy of Xianling Gubao Capsule Combined with Denosumab in the Treatment of Postmenopausal Osteoporosis and Its Impact on Bone Metabolism. Clinical Rational Drug Use, 18(34): 132-134+145.

[2] Huang ZP, Song MY, Zhao XL, et al., 2024, Observation on the Effect of Denosumab Combined with Percutaneous Kyphoplasty in the Treatment of Osteoporotic Vertebral Compression Fractures in Elderly Women. Practical Gerontology, 38(12): 1238-1241.

[3] Sun SX, Zhu J, Kong DQ, et al., 2024, Analysis of the Postoperative Efficacy and Safety of Denosumab in the Treatment of Osteoporotic Intertrochanteric Fractures in Elderly Women. International Journal of Orthopedics, 45(6): 413-416.

[4] Chen GX, Qiu LL, 2024, The Therapeutic Effect of Denosumab Injection Combined with Baduanjin on Osteoporosis in Postmenopausal Women. Chinese Contemporary Medicine, 31(23): 71-74.

[5] Zhang MQ, Jiang XB, He XN, 2024, Cost-Effectiveness Analysis of Denosumab in the Treatment of Chinese Male and Postmenopausal Female Patients with Osteoporosis. Chinese Pharmaceutical Journal, 59(11): 1057-1064.

[6] Yan C, Du XT, Liu Y, et al., 2024, The Efficacy of Denosumab Treatment in Elderly Women after Osteoporotic Vertebral Compression Fracture. Practical Gerontology, 38(3): 296-298.

[7] Lin Y, Liu XY, 2024, Clinical Pharmacists Participated in the Pharmaceutical Care of a Patient with Severe Osteoporosis Treated with Denosumab. Shanghai Medicine, 45(5): 70-72.

[8] Wang JW, Xu GZ, Ning WH, 2023, Observation on the Effect of Denosumab after Percutaneous Vertebroplasty in Postmenopausal Women with Osteoporotic Thoracolumbar Fractures. Chinese Journal of Bone and Joint Injury, 38(11): 1168-1170.

[9] Zhang WL, 2023, Observation on the Efficacy of Denosumab and Its Combination with Bisphosphonates in the Treatment of Osteoporosis in Postmenopausal Women. Clinical Medical Practice, 32(6): 431-434.

[10] Zhang Q, Cui RH, He LX, et al., 2023, The Efficacy of Aclasta and Denosumab in the Treatment of Osteoporosis in Menopausal Women and Their Impact on Serum Bone Metabolism Markers in Patients. Journal of Clinical Military Medicine, 51(6): 652-654.

Share
Back to top